$434.52
0.08% yesterday
Nasdaq, Nov 13, 10:12 pm CET
ISIN
US92532F1003
Symbol
VRTX

Vertex Pharmaceuticals Stock price

$434.52
+27.15 6.66% 1M
+2.52 0.58% 6M
+31.82 7.90% YTD
-60.09 12.15% 1Y
+128.49 41.99% 3Y
+209.00 92.67% 5Y
+311.47 253.12% 10Y
+408.33 1,559.11% 20Y
Nasdaq, Closing price Thu, Nov 13 2025
+0.33 0.08%
ISIN
US92532F1003
Symbol
VRTX
Industry

New AI Insights on Vertex Pharmaceuticals Insights AI Insights on Vertex Pharmaceuticals

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$105.6b
Enterprise Value
$99.3b
Net debt
-
Cash
$6.3b
Shares outstanding
254.0m
Valuation (TTM | estimate)
P/E
30.4 | 23.6
P/S
9.0 | 8.6
EV/Sales
8.5 | 8.1
EV/FCF
29.8
P/B
6.1
Financial Health
Equity Ratio
72.8%
Return on Equity
-3.3%
ROCE
22.3%
ROIC
26.6%
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$11.7b | $12.2b
EBITDA
$4.7b | $5.5b
EBIT
$4.5b | $5.4b
Net Income
$3.7b | $4.7b
Free Cash Flow
$3.3b
Growth (TTM | estimate)
Revenue
10.3% | 11.0%
EBITDA
5.1% | 20.5%
EBIT
5.8% | 22.7%
Net Income
866.0% | 971.6%
Free Cash Flow
346.9%
Margin (TTM | estimate)
Gross
86.3%
EBITDA
40.4% | 45.3%
EBIT
38.7%
Net
31.4% | 38.2%
Free Cash Flow
28.5%
More
EPS
$14.3
FCF per Share
$13.1
Short interest
1.8%
Employees
6k
Rev per Employee
$1.8m
Show more

Create a Free Account to create an Vertex Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Vertex Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

39 Analysts have issued a Vertex Pharmaceuticals forecast:

25x Buy
64%
13x Hold
33%
1x Sell
3%

Analyst Opinions

39 Analysts have issued a Vertex Pharmaceuticals forecast:

Buy
64%
Hold
33%
Sell
3%

Financial data from Vertex Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
11,723 11,723
10% 10%
100%
- Direct Costs 1,609 1,609
9% 9%
14%
10,115 10,115
11% 11%
86%
- Selling and Administrative Expenses 1,644 1,644
13% 13%
14%
- Research and Development Expense 3,935 3,935
14% 14%
34%
4,737 4,737
5% 5%
40%
- Depreciation and Amortization 201 201
9% 9%
2%
EBIT (Operating Income) EBIT 4,536 4,536
6% 6%
39%
Net Profit 3,675 3,675
866% 866%
31%

In millions USD.

Don't miss a Thing! We will send you all news about Vertex Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vertex Pharmaceuticals Stock News

Neutral
Seeking Alpha
one day ago
Class A shares of the Alger Weatherbie Specialized Growth Fund underperformed the Russell 2500 Growth Index during the third quarter of 2025. Semtech Corporation (SMTC), Impinj Inc. (PI), and Artivion, Inc. (AORT) were among the top contributors to performance. SPS Commerce, Inc. (SPSC), Palomar Holdings, Inc. (PLMR), and Vertex, Inc. (VRTX) were among the top detractors from performance.
Neutral
Seeking Alpha
2 days ago
Vertex Pharmaceuticals Incorporated ( VRTX ) UBS Global Healthcare Conference 2025 November 11, 2025 10:15 AM EST Company Participants Reshma Kewalramani - CEO, President & Director Conference Call Participants Dina Elmonshed Presentation Dina Elmonshed Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS.
Neutral
Seeking Alpha
5 days ago
Vertex Pharmaceuticals Incorporated ( VRTX ) Discusses Updated Data for Pove in IgAN and pMN and Developments in Kidney Disease Portfolio November 8, 2025 8:00 PM EST Company Participants Susie Lisa - Senior Vice President of Investor Relations Reshma Kewalramani - CEO, President & Director Conference Call Participants James A. Tumlin Richard Lafayette Brad Rovin Carter Gould - Cantor Fitzgeral...
More Vertex Pharmaceuticals News

Company Profile

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Head office United States
CEO Reshma Kewalramani
Employees 6,100
Founded 1989
Website www.vrtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today